US4524068A - Cyclodextrin inclusion complex of piperonyl butoxide - Google Patents
Cyclodextrin inclusion complex of piperonyl butoxide Download PDFInfo
- Publication number
- US4524068A US4524068A US06/550,478 US55047883A US4524068A US 4524068 A US4524068 A US 4524068A US 55047883 A US55047883 A US 55047883A US 4524068 A US4524068 A US 4524068A
- Authority
- US
- United States
- Prior art keywords
- piperonyl butoxide
- cyclodextrin
- complex
- butoxide
- piperonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
- A01N43/24—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms
- A01N43/26—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms five-membered rings
- A01N43/28—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms five-membered rings with two hetero atoms in positions 1,3
- A01N43/30—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with two or more hetero atoms five-membered rings with two hetero atoms in positions 1,3 with two oxygen atoms in positions 1,3, condensed with a carbocyclic ring
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/54—Radicals substituted by oxygen atoms
Definitions
- This invention relates to cyclodextrin inclusion complexes of piperonyl butoxide and a process for the preparation thereof.
- piperonyl butoxide is a frequently used synergistic component of several insecticidal combinations.
- the chemical nomenclature of piperonyl butoxide is 5- ⁇ [2-(2-butoxy-ethoxy)-ethoxy]-methyl ⁇ -6-propyl-1,3-benzodioxole, while the IUPAC name thereof is 5-[2(2-butoxy-ethoxy)-ethoxy-methyl]-6-propyl-1,3-benzodioxole.
- piperonyl butoxide-- may be used in a ratio of 5-20 parts by weight--preferably 8 parts by weight--related to 1 part by weight of active ingredient.
- the synergistic agents--such as piperonyl butoxide-- have a negligible toxicity.
- Piperonyl butoxide is generally used to synergize pyrethrines and synthetic pyrethroides and organic phosphate compositions.
- PBO piperonyl butoxide
- Piperonyl butoxide is a colorless liquid, its boiling point amounts to 180° C., it is soluble in organic solvents and substantially insoluble in water. When shaken in distilled water at 25° C. for an hour the solubility amounts but to 0.066 mg/ml--determined on the basis of the UV absorption measured at a wavelength of 238 or 310 nm. Since the molecule is absorbed in the organism of the insects through aqueous phase, the extremely low water-solubility inhibits and slows the absorption of the synergistic component to a large extent. Probably this the reason of the necessity of using the synergistic agent in such a high amount related to the active ingredient.
- a process for the preparation of an inclusion complex of piperonyl butoxide and cyclodextrin which comprises reacting cyclodextrine or a solution thereof formed with water and/or an organic solvent having 1-4 carbon atoms, preferably ethanol with piperonyl butoxide or a solution thereof formed with an organic solvent having 1-4 carbon atoms, preferably ethanol at a temperature between 20° C. and 90° C., whereby the piperonyl butoxide is used in an amount of 0.6-1.5 moles related to 1 mole of cyclodextrin.
- the process of the present invention can be carried out by two methods.
- cyclodextrin is reacted with piperonyl butoxide either in solution or in the absence of a solvent by kneading.
- the formed cyclodextrin inclusion complex is separated and dried in a vacuum exsiccator.
- cyclodextrin ⁇ -, ⁇ - or ⁇ -cyclodextrin or a mixture thereof or any intermediate or mother-lye or cyclodextrin production can be used.
- the advantages of the piperonyl butoxide-cyclodextrin inclusion complex of the present invention over the piperonyl butoxide molecule can be summarized as follows:
- the inclusion complexes are solid crystalline products, which can be easily handled and readily formulated.
- the amount of piperinyl butoxide which can be dissolved from the inclusion complex is by 2.5 to 4 times larger than the amount of pure piperonyl butoxide dissolved in aqueous solution.
- the piperonyl butoxide-cyclodextrin inclusion complex of the present invention can replace the original synergistic agent in insecticidal or fungicidal combinations to synergize the activity of pyrethrines, synthetic pyrethroides or organophosphates.
- the piperonyl butoxide content of the complex amounts to 26.5%, determined by measuring the UV spectrum of a solution of the complex in 48% ethanol (concentration 0.1 mg/ml).
- the solubility of the complex at 25° C. is 0.165 mg/ml (measured by shaking for an hour).
- the UV spectrum of piperonyl butoxide shows absorption maxima at 238 and 310 nm.
- the calibration curve of a 48% ethanolic solution is prepared in a concentration range of 0.01-0.10 mg/ml. From the tangent of the calibration curve the concentration can be calculated by means of the following relationships:
- the solubility of the complex is 0.165 mg/ml at 20° C. as measured by shaking for an hour.
- the piperonyl butoxide content of the complex amounts to 20% which corresponds to a molar ratio of 0.84 mole of PBO/1 mole of ⁇ -cyclodextrin.
- the solubility of the complex amounts to 0.165 mg/ml, at 20° C., measured by shaking for an hour.
- the piperonyl butoxide content of the complex amounts to 20.5% which corresponds to a molar ratio of 0.87 mole of PBO/1 mole of ⁇ -cyclodextrin.
- the solubility of the complex is 0.165 mg/ml, at 25° C., measured by shaking for an hour.
- the synergistic effect of piperonyl butoxide on the insecticidally active tetrametrin is compared to that of the complex.
- the insecticidal effect of the combinations comprising tetrametrin and piperonyl butoxide or the complex, respectively on Drosophila melanogaster Meigen (vinegar midge) is determined and the so-called "knock-down" effect (the insect being lying on its back is unable to turn back) and 24 hours' killing effect (mortality), are evaluated.
- the 3-4 days' old midges are divided into two groups.
- One group is fed for 24 hours before treatment with an emulsion of piperonyl butoxide (concentration 10 mg/ml), while the other with a suspension (50 mg/ml) having the same piperonyl butoxide content but containing the piperonyl butoxide-cyclodextrin complex prepared according to Example 4.
- the emulsion and suspension also contain 5% of sucrose.
- the knock-down effect is continuously evaluated from the 30th minute for 6 hours by counting the knocked-down insects. Next day the 24 hours' mortality is determined. During treatment a 15% sucrose solution serves as foodstuff for the insects and as source of humidity.
- the tetrametrin doses used in the test are identical with those in Example 8.
- the synergistic agent is used however in a four times larger amount.
- the ratio between the pyrethronide and the synergistic agent amounts to 1:4.
- Two series of filter paper disks are treated with tetrametrin doses being identical with those of Example 8 by adding dropwise 1 ml of acetonic tetrametrin solutions of different dilution onto each disk.
- the solvent is evaporated, whereupon 4 ml of an acetonic piperonyl butoxide solution (concentration 10 mg/ml) are poured onto each disk of one series and 4 ml of an aqueous suspension of the piperonyl butoxide/cyclodextrin complex (concentration 50 mg/ml) are added dropwise onto each disk of the second series.
- the insects slightly narcotized with ether are placed onto these poisoned area. From the 40th minute the knock-down effect is continuously read-off and the total activity (percentage of the paralitic and killed insects) is evaluated in the sixth hour.
- a 5% sucrose solution serves as foodstuff for the insects and as humidity source.
- the test has two objects; on one hand to determine the synergistic effect of piperonyl butoxide and the piperonyl butoxide/cyclodextrin complex, respectively, while on the other hand to demonstrate the increased synergistic activity of the inclusion complex of piperonyl butoxide and cyclodextrin.
- Piperonyl butoxide and the complex of piperonyl butoxide and cyclodextrin are applied as described in Example 9.
- the ratio of pyrethroide and synergistic agent amounts to 1:4 in all cases.
- the efficiency of insecticidal effect is proportional to the value of the 24 hours' mortality (killing effect).
- the synergistic activity of the inclusion complex formed with cyclodextrin is significantly higher than that of free piperonyl butoxide.
- the 24 hours' killing values are namely higher, thus an identical effect can be obtained with the aid of a smaller dose (Table 5).
- the 50% knock-down effect is separately marked.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Abstract
The invention relates to new inclusion complexes of piperonyl butoxide formed with cyclodextrin.
The new complex of the invention can be prepared by reacting cyclodextrin or a solution thereof formed with water and/or an organic solvent having 1-4 carbon atoms, preferably ethanol with piperonyl butoxide or a solution thereof formed with an organic solvent having 1-4 carbon atoms, preferably ethanol at a temperature between 20° C. and 90° C., whereby the piperonyl butoxide is used in an amount of 0.6-1.5 moles related to 1 mole of cyclodextrin.
The complexes of the present invention synergize the pesticidal effect of known insecticides and fungicides to a much higher extent of known insecticides and fungicides to a much higher extent than piperonyl butoxide used per se.
Description
This invention relates to cyclodextrin inclusion complexes of piperonyl butoxide and a process for the preparation thereof.
It is known that piperonyl butoxide is a frequently used synergistic component of several insecticidal combinations. The chemical nomenclature of piperonyl butoxide is 5-{[2-(2-butoxy-ethoxy)-ethoxy]-methyl}-6-propyl-1,3-benzodioxole, while the IUPAC name thereof is 5-[2(2-butoxy-ethoxy)-ethoxy-methyl]-6-propyl-1,3-benzodioxole.
Numerous efficient insecticidal active ingredients are decomposed by the mitochondrial non-specific oxidative enzymes of the insects so rapidly that the exerted effect is very low. The synergistic effect of piperonyl butoxide and other similar synergistic components manifests itself in the fact that the said agent inhibit the rapid inactivation of the active ingredient by the oxidase enzymes of mixed function. The said synergistic agents are useful not only in combination with insecticides but also with fungicides and they are capable of increasing the effect of the active ingredient by ten to fifty times. The amount of the synergistic component related to the active ingredient is large. Thus in solutions, aerosols, emulsions and powder mixtures the synergistic agent--e.g. piperonyl butoxide--may be used in a ratio of 5-20 parts by weight--preferably 8 parts by weight--related to 1 part by weight of active ingredient. The synergistic agents--such as piperonyl butoxide--have a negligible toxicity.
Piperonyl butoxide is generally used to synergize pyrethrines and synthetic pyrethroides and organic phosphate compositions. Studies relating to the relationship between the synergistic effect and chemical structure of piperonyl butoxide (referred to furtheron as "PBO") have shown that the methylenedioxy phenyl group is the most important functional moiety of the molecule and that any modification or change of the said group leads to the complete loss or strong reduction of the synergistic activity. The substituents of the aryl ring ensure the lipophility required to the penetration of the molecule.
Piperonyl butoxide is a colorless liquid, its boiling point amounts to 180° C., it is soluble in organic solvents and substantially insoluble in water. When shaken in distilled water at 25° C. for an hour the solubility amounts but to 0.066 mg/ml--determined on the basis of the UV absorption measured at a wavelength of 238 or 310 nm. Since the molecule is absorbed in the organism of the insects through aqueous phase, the extremely low water-solubility inhibits and slows the absorption of the synergistic component to a large extent. Probably this the reason of the necessity of using the synergistic agent in such a high amount related to the active ingredient.
It is known that the active ingredients of drugs and pesticides can be included into cyclodextrines and the inclusion complexes thus obtained can influence and modify the biological characteristics thereof. (Die Starke 33, 1981; British Pat. No. 1.451.813).
It has been found that the solubility of piperonyl butoxide (PBO) and other similar synergistic agents can be increased by forming a cyclodextrin complex. The inclusion complex goes into solution more rapidly and thereby the velocity of penetration through the biological membrane is increased as well. The absolute activity of the synergistic component becomes higher and therefore in an identical active ingredient concentration the biological effect is exhibited more promptly and stronger or the same biological effect can be reached by using a lower active ingredient concentration.
According to the present invention there are provided inclusion complexes of piperonyl butoxide and cyclodextrin.
According to a further feature of the present invention there is provided a process for the preparation of an inclusion complex of piperonyl butoxide and cyclodextrin which comprises reacting cyclodextrine or a solution thereof formed with water and/or an organic solvent having 1-4 carbon atoms, preferably ethanol with piperonyl butoxide or a solution thereof formed with an organic solvent having 1-4 carbon atoms, preferably ethanol at a temperature between 20° C. and 90° C., whereby the piperonyl butoxide is used in an amount of 0.6-1.5 moles related to 1 mole of cyclodextrin.
The process of the present invention can be carried out by two methods. Thus cyclodextrin is reacted with piperonyl butoxide either in solution or in the absence of a solvent by kneading. In both cases the formed cyclodextrin inclusion complex is separated and dried in a vacuum exsiccator.
As cyclodextrin α-, β- or γ-cyclodextrin or a mixture thereof or any intermediate or mother-lye or cyclodextrin production can be used. The advantages of the piperonyl butoxide-cyclodextrin inclusion complex of the present invention over the piperonyl butoxide molecule can be summarized as follows:
(1) The inclusion complexes are solid crystalline products, which can be easily handled and readily formulated.
(2) The amount of piperinyl butoxide which can be dissolved from the inclusion complex is by 2.5 to 4 times larger than the amount of pure piperonyl butoxide dissolved in aqueous solution.
(3) As a result of the higher water solubility the absorption of the synergistic agent is increased and the velocity of penetration through the biological membrane becomes larger and consequently the absolute concentration of the active ingredient increases as well.
(4) As a consequence of the aforesaid when using identical active ingredient concentration the biological effect is quicker and stronger and an identical active biological effect can be achieved with the aid of a lower active ingredient concentration.
The piperonyl butoxide-cyclodextrin inclusion complex of the present invention can replace the original synergistic agent in insecticidal or fungicidal combinations to synergize the activity of pyrethrines, synthetic pyrethroides or organophosphates.
Further details of the present invention are to be found in the following Examples without limiting the scope of protection to the said Examples.
10 g (8.81 millimoles) of β-cyclodextrin are dissolved in 100 ml of distilled water at 60°-70° C. To the warm solution a solution of 4 ml (4.22 g, 12.48 millimoles) of piperonyl butoxide in 100 ml of 96% by vol. ethanol is slowly added under constnt stirring. The mixture is allowed to cool to ambient temperature under further stirring, the precipitated crystals are filtered off and dried in a vacuum exsiccator over phosphorous pentoxide. Thus 11.58 g of an inclusion complex of β-cyclodextrin and piperonyl butoxide are obtained.
The piperonyl butoxide content of the complex amounts to 26.5%, determined by measuring the UV spectrum of a solution of the complex in 48% ethanol (concentration 0.1 mg/ml). The solubility of the complex at 25° C. is 0.165 mg/ml (measured by shaking for an hour).
The UV spectrum of piperonyl butoxide shows absorption maxima at 238 and 310 nm. In order to carry out quantitative spectrophotometrical determination the calibration curve of a 48% ethanolic solution is prepared in a concentration range of 0.01-0.10 mg/ml. From the tangent of the calibration curve the concentration can be calculated by means of the following relationships:
c=0.069696.E238 or
c=0.08547.E310.
10 g (8.81 millimoles) of β-cyclodextrin are dissolved in 48% by Vol. ethanol at 60°-70° C. To this solution a solution of 4 ml (4.22 g, 12.48 millimoles) of piperonyl butoxide in 48% ethanol (1:1 Vol.ratio) is slowly added under stirring. The reaction mixture is worked up as described in Example 1.
Thus 11.36 g of an inclusion complex of β-cyclodextrin and piperonyl butoxide are obtained. The piperonyl butoxide content of the complex amounts to 30.8% which corresponds to a molar ratio of 1.49 moles of PBO/1 mole of β-cyclodextrin.
The solubility of the complex is 0.165 mg/ml at 20° C. as measured by shaking for an hour.
1.5 g (1.16 millimoles) of γ-cyclodextrin are dissolved in 10 ml of distilled water at room temperature whereupon a solution of 0.5 ml (0.53 g, 1.56 millimoles) of piperonyl butoxide in 10 ml of 96% by Vol. ethanol is added. One proceeds furtheron as described in Example 1. Thus 1.32 g of an inclusion complex of γ-cyclodextrin and piperonyl butoxide are obtained. The piperonyl butoxide content of the complex amounts to 26.5% which corresponds to a molar ratio of 1.38 moles of PBO/1 moles of γ-cyclodextrin. The solubility of the complex is 0.165 mg/ml, at 20° C., as measured by shaking for an hour.
20 g (17.62 millimoles) of β-cyclodextrin and 5 ml (5.3 g, 15.6 millimoles) of piperonyl butoxide are homogenized in a pug mill under intensive kneading, whereupon the mixture is dried in a vacuum exsiccator over phosphorous pentoxide. Thus 25.1 g of an β-cyclodextrin-piperonyl butoxide inclusion complex are obtained. The product is a white crystalline not moist substance which is a little oily to the touch. The piperonyl butoxide content of the complex amounts to 20% which corresponds to a molar ratio of 0.84 mole of PBO/1 mole of β-cyclodextrin. The solubility of the complex amounts to 0.165 mg/ml, at 20° C., measured by shaking for an hour.
1 g (0.77 millimole) of γ-cyclodextrin are homogenized under kneading with 0.2 ml (0.21 g, 0.62 millimole) of piperonyl butoxide and dried as described in Example 4.
Thus 1.18 g of an inclusion complex of γ-cyclodextrin and piperonyl butoxide are obtained in the form of a white crystalline substance which is oily to the touch but not moist. The piperonyl butoxide content of the complex amounts to 16.7% which corresponds to a molar ratio of 0.78 mole of PBO/1 mole of γ-cyclodextrin. The solubility of the complex amounts to 0.165 mg/ml, at 20° C. measured by shaking for an hour.
10 g (8.81 millimoles) of β-cyclodextrin are dissolved in 80 ml of distilled water at 80°-90° C. under constant stirring. Thereafter 5 ml (5.3 g, 15.6 millimoles) of piperonyl butoxide are slowly poured in the solution under stirring, the mixture is stirred at 80°-90° C. for a further hour and allowed to cool to room temperature under steady stirring. The precipitated complex of β-cyclodextrin and piperonyl butoxide are obtained in the form of a white crystalline powder. The piperonyl butoxide content of the complex amounts to 20.5% which corresponds to a molar ratio of 0.87 mole of PBO/1 mole of β-cyclodextrin. The solubility of the complex is 0.165 mg/ml, at 25° C., measured by shaking for an hour.
4 g (4.11 moles) of α-cyclodextrin are homogenized under kneading with 1 ml (1.05 g, 3.12 millimoles) of piperonyl butoxide and dried as described in Example 4.
Thus 4.8 g of an inclusion complex of α-cyclodextrin and piperonyl butoxide are obtained. The white crystals are oily to the touch but not moist. The piperonyl butoxide content of the complex amounts to 20% which corresponds to a molar ratio of 0.72 mole of PBO/1 mole of α-cyclodextrin. The amount of piperonyl butoxide which can be dissolved from the complex by shaking for an hour at 25° C. is 0.165 mg/ml.
In order to demonstrate the increased biological effect of the piperonyl butoxide-cyclodextrin complex of the present invention the synergistic effect of piperonyl butoxide on the insecticidally active tetrametrin is compared to that of the complex. The insecticidal effect of the combinations comprising tetrametrin and piperonyl butoxide or the complex, respectively on Drosophila melanogaster Meigen (vinegar midge) is determined and the so-called "knock-down" effect (the insect being lying on its back is unable to turn back) and 24 hours' killing effect (mortality), are evaluated.
The following method generally used in testing gastric toxicity is applied as follows:
The 3-4 days' old midges are divided into two groups. One group is fed for 24 hours before treatment with an emulsion of piperonyl butoxide (concentration 10 mg/ml), while the other with a suspension (50 mg/ml) having the same piperonyl butoxide content but containing the piperonyl butoxide-cyclodextrin complex prepared according to Example 4. The emulsion and suspension also contain 5% of sucrose.
From an acetonic stock solution (10 mg/ml) of tetrametrin the following series of dilution is prepared by the double-fold dilution method:
Concentration mg/ml: 5.000; 2.500; 1.250; 0.625; 0.313; 0.156; 0.078.
1 ml of the said solutions each is poured onto filter paper disks (diameter 9 cm) placed into Petri dishes. The insects slightly narcotized with ether are placed onto these dried disks.
The knock-down effect is continuously evaluated from the 30th minute for 6 hours by counting the knocked-down insects. Next day the 24 hours' mortality is determined. During treatment a 15% sucrose solution serves as foodstuff for the insects and as source of humidity.
Although the differences in the mortality data are slight (Table 1), the results obtained in the knock-down effect (promptness of effect) on both tests is significantly different. Thus in the doses applied the knock-down effect of the combination of tetrametrin and the piperonyl butoxide/cyclodextrin complex is much stronger than that obtained on insects pre-fed with a combination of tetrametrin and piperonyl butoxide (Table 2).
TABLE 1
______________________________________
Mortality (24 hours mortality; killing effect, %) of
tetrametrin on Drosophila melabogaster Meigen (vinegar
midge) pre-fed with piperonyl butoxide and an inclusion
complex of piperonyl butoxide and cyclodextrin, respectively.
tetrametrin dose [mg/disk]
Pre-fed with
5.000 2.500 1.250
0.625
0.313
0.156
0.078
______________________________________
piperonyl- 100 100 100 68 38 30 6
butoxide/-cyclo-
dextrin complex
piperonyl- 100 100 100 48 34 8 0
butoxide
______________________________________
In a dose of 5.000 mg/disk a 50% knock-down effect can be reached with the aid of tetrametrin synergized by the complex by 1.5-2.0 times more rapidly than by using tetrametrin synergized by free piperonyl butoxide. In doses of 2.5 mg/disk and 1.25 mg/disk the difference between the knock-down effect is still more striking, namely 3-4 times more rapid in favor of the complex.
TABLE 2
______________________________________
Knock-down effect (%) of tetrametrin on Drosophila
melanogaster Meigen (vinegar midge) pre-fed with piperonyl
butoxide and a complex of piperonyl butoxide and cyclo-
dextrin, respectively.
pre-fed with piperonyl-
butoxide/cyclodextrine
pre-fed with
complex piperonyl-butoxide
tetrametrine dose
tetrametrine dose
Time [mg/disk] [mg/disk]
(minutes)
5.002.501.25 5.002.501.25
______________________________________
304050
##STR1##
##STR2##
6080100
##STR3##
##STR4##
140180200
##STR5##
##STR6##
220260330
##STR7##
##STR8##
______________________________________
The synergistic effect of the piperonyl butoxide/cyclodextrin complex and piperonyl butoxide, respectively on the insecticide tetrametrin is determined and compared in an analogous manner to Example 8. As test insect Drosophila melanogaster Meigen is ued.
The tetrametrin doses used in the test are identical with those in Example 8. The synergistic agent is used however in a four times larger amount. Thus the ratio between the pyrethronide and the synergistic agent amounts to 1:4. Two series of filter paper disks are treated with tetrametrin doses being identical with those of Example 8 by adding dropwise 1 ml of acetonic tetrametrin solutions of different dilution onto each disk. The solvent is evaporated, whereupon 4 ml of an acetonic piperonyl butoxide solution (concentration 10 mg/ml) are poured onto each disk of one series and 4 ml of an aqueous suspension of the piperonyl butoxide/cyclodextrin complex (concentration 50 mg/ml) are added dropwise onto each disk of the second series. The insects slightly narcotized with ether are placed onto these poisoned area. From the 40th minute the knock-down effect is continuously read-off and the total activity (percentage of the paralitic and killed insects) is evaluated in the sixth hour. During the treatment a 5% sucrose solution serves as foodstuff for the insects and as humidity source.
The synergistic effect of the complex is significantly higher than that of free piperonyl butoxide. Thus the synergistic activity is stronger (Table 3), the effect is prompter, and the knockdown-effect is considerably more favorable (see Table 4).
TABLE 3
______________________________________
Insecticidal effect of combinations of tetrametrin and
piperonyl butoxide and tetrametrin and piperonyl
butoxide/cyclodextrin complex, respectively on Drosophila
melanogaster Meigen (vinegar midge)
Paralyzed and killed insects (%)
synergistic tetrametrine dose [mg/disk]
afert 5.000 2.500 1.250
0.625
0.313
0.156
0.078
______________________________________
piperonyl- 88 40 14 10 0 0 0
butoxide
piperonyl- 100 90 88 24 16 4 0
butoxide/cyclo-
dextrin complex
______________________________________
TABLE 4
______________________________________
Knock-down effect of combinations of tetrametrin and
piperonyl butoxide and tetrametrin and a complex of
piperonyl butoxide and cyclodextrin, respectively on
Drosophila melanogaster Meigen (vinegar midge)
tetrametrin + piperonyl-
tetrametrin + piperonyl
butoxide/cyclo-
butoxide dextrine complex
Time tetrametrine dose
(minutes)
5.00 2.50 1.25 5.002.501.25
______________________________________
40 70100140
0 61035 0000 0002
##STR9##
180210240270
##STR10##
8111213
6 101012
##STR11##
300330360
##STR12##
181840 121414
##STR13##
______________________________________
*= pyrethroide:synergistic agent = 1:4
The test has two objects; on one hand to determine the synergistic effect of piperonyl butoxide and the piperonyl butoxide/cyclodextrin complex, respectively, while on the other hand to demonstrate the increased synergistic activity of the inclusion complex of piperonyl butoxide and cyclodextrin.
As insecticide tetrametrin and cinerin I are used. The insecticidal effect is tested on 2-4 weeks' old Sitophilus granarius (Corn-Weevil) imago.
Piperonyl butoxide and the complex of piperonyl butoxide and cyclodextrin are applied as described in Example 9. The ratio of pyrethroide and synergistic agent amounts to 1:4 in all cases. The efficiency of insecticidal effect is proportional to the value of the 24 hours' mortality (killing effect).
The synergistic activity of the inclusion complex formed with cyclodextrin is significantly higher than that of free piperonyl butoxide. The 24 hours' killing values are namely higher, thus an identical effect can be obtained with the aid of a smaller dose (Table 5). The 50% knock-down effect is separately marked.
The higher efficiency is accompanied by an outstandingly striking increase of knock-down effect. Thus with the aid of insecticides synergised by a complex of piperonyl butoxide and cyclodextrin a stronger effect can be achieved with in a shorter time (Table 6).
TABLE 5
______________________________________
24 hours' mortality of tetrametrin and cinerin synergized
by piperonyl butoxide (PBO) and a complex of piperonyl
butoxide and cyclodextrin (PBO--CD), respectively, on
Sitophilus granarius.
Paralitical and killed insects, %
pyrethroide dose [mg/disk]
Treatment 10.000 5.0002.500 1.250 0.625
______________________________________
tetrametrintetrametrin + PBOtetrametrin +PBOCD
41----
##STR14##
##STR15##
-- 018
cinerincinerin + PBOcinerin + PBOCD
31----
##STR16## 0 324 -- 0 0
______________________________________
TABLE 6 ______________________________________ Knock-down effect of tetrametrin and cinerin I synergized with piperonyl butoxide and a complex of piperonyl butoxide and cyclodextrin, respectively, on Sitophilus granarius; the ratio of pyrethroide and synergistic agent amounts to 1:4. Time tetrametrin cinerin (minutes) +PBO +PBO--CD +PBO +PBO--CD ______________________________________ 90 0 10 16 6 0 8 170 9 17 76 9 2 10 210 9 10 84 8 7 35 300 6 10 100 2 7 53 ______________________________________
One proceeds according to the preceding Example except that the insecticide carbofuran and the synergistic agent are used in a ratio of 1:0.5.
It can be seen from Table 7 that the synergistic effect of the complex on carbofuran is superior to that of free piperonyl butoxide. The favorable effect of complex formation also appears from Table 8 where the course of toxicity of similar severity are compared. The 50% knock-down effects are separately marked.
TABLE 7
______________________________________
24 hours' mortality (killing effect) of carbofuran
synergized by piperonyl butoxide and a complex of
piperonyl butoxide and cyclodextrin, respectively, on
Sitophilus granarius; ratio of carbofuran and piperonyl
butoxide = 1:0.5.
Paralyzed and killed insects, %
carbofuran dose [mg/disk]
Treatment 5.000 2.500 1.2500.625
0.313
0.156
______________________________________
CarbofuranCarbofuran + PBOCarbofuran +PBOCD
100100100
100100100
##STR17##
000 000
______________________________________
TABLE 8
______________________________________
Course of toxicity caused by carbofuran synergized by
piperonyl butoxide and a complex of piperonyl butoxide
cyclodextrin, respectively, on Sitophilus
granarius. Ratio of carbofuran to synergistic agent = 1:0.5.
Dose of carbofuran = 2.5 mg/disk
Time Carbofuran
(minutes)
+ PBO+ PBOCD
______________________________________
90 009
150210280350400
##STR18##
1440 100100100
______________________________________
Claims (4)
1. An inclusion complex of piperonyl butoxide and cyclodextrin, wherein the piperonyl butoxide is present in an amount of 0.6 to 1.5 moles relative to 1 mole of cyclodextrin.
2. Inclusion complex according to claim 1 wherein the cyclodextrin is α-cyclodextrin.
3. Inclusion complex according to claim 1 wherein the cyclodextrin is β-cyclodextrin.
4. Inclusion complex according to claim 1 wherein the cyclodextrin is γ-cyclodextrin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU823597A HU190818B (en) | 1982-11-09 | 1982-11-09 | Process for producing complexes of piperonyl-butoxide-cyclodextrin |
| HU3597/82 | 1982-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4524068A true US4524068A (en) | 1985-06-18 |
Family
ID=10964720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/550,478 Expired - Fee Related US4524068A (en) | 1982-11-09 | 1983-11-09 | Cyclodextrin inclusion complex of piperonyl butoxide |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4524068A (en) |
| JP (1) | JPS59152381A (en) |
| DE (1) | DE3339840A1 (en) |
| FR (1) | FR2535720B1 (en) |
| GB (1) | GB2131426B (en) |
| HU (1) | HU190818B (en) |
Cited By (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4672112A (en) * | 1984-06-08 | 1987-06-09 | Magyar Tudomenyos Akademia Novenyvedelmi Kutato Intezete | β-Cyclodextrine complex of benzene sulphonyl urea derivatives |
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4775749A (en) * | 1983-08-08 | 1988-10-04 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Inclusion compound of eicosapentaenoic of acid and food product containing the same |
| US4923853A (en) * | 1985-01-07 | 1990-05-08 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. | Process for enhancing the activity of plant protecting agents by using cyclodextrin |
| US4935407A (en) * | 1986-09-23 | 1990-06-19 | Akzo N.V. | Thermochemiluminescent cyclodextrin complexes |
| US4950682A (en) * | 1988-02-05 | 1990-08-21 | Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. | Arthropodicidal compositions |
| US4983586A (en) * | 1987-12-30 | 1991-01-08 | University Of Florida | Pharmaceutical formulations for parenteral use |
| US5017566A (en) * | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| US5079000A (en) * | 1988-11-24 | 1992-01-07 | Kurita Water Industries Ltd. | Clathrate composition including essential oils and method of using same |
| US5221735A (en) * | 1991-02-25 | 1993-06-22 | Hoffmann-La Roche Inc. | Cyclodextrin-polyene inclusion complexes |
| US5314877A (en) * | 1990-11-21 | 1994-05-24 | Hokkaido Sugar Co., Ltd. | Water-soluble pentacyclic triterpene composition and method for producing the same |
| US5506216A (en) * | 1993-04-23 | 1996-04-09 | Boehringer Mannheim Gmbh | Cyclodextrin-biocide complex |
| US5730969A (en) * | 1988-10-05 | 1998-03-24 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5804568A (en) * | 1992-06-19 | 1998-09-08 | Supergen, Inc. | Pharmaceutical formulation |
| US5824668A (en) * | 1996-11-07 | 1998-10-20 | Supergen, Inc. | Formulation for administration of steroid compounds |
| FR2780889A1 (en) * | 1998-07-10 | 2000-01-14 | Concept | USE OF A P450 CYTOCHROME INHIBITOR IN ASSOCIATION WITH AN ANTIFUNGAL FOR THE TREATMENT OF MYCOSES |
| US20020068720A1 (en) * | 2000-08-22 | 2002-06-06 | Sims Sandra M. | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading |
| US20040014695A1 (en) * | 1992-06-19 | 2004-01-22 | Supergen, Inc. | Pharmaceutical formulation |
| US20040071775A1 (en) * | 2001-07-31 | 2004-04-15 | Zhiwei Jiang | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| US20040242699A1 (en) * | 2003-05-28 | 2004-12-02 | Bug Buster Ltd. | Compounds to affect insect behavior and to enhance insecticides |
| WO2005039287A2 (en) | 2003-10-27 | 2005-05-06 | Endura S.P.A. | Formulation of a synergistic insecticidal composition as a cyclodextrin-complex |
| US6962944B2 (en) | 2001-07-31 | 2005-11-08 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| US20060189690A1 (en) * | 2003-11-14 | 2006-08-24 | Dunham Charles F | Compounds to affect insect behavior and/or bird behavior |
| WO2006111570A2 (en) | 2005-04-22 | 2006-10-26 | Endura S.P.A. | Biologically active formulation based on cyclodextrin supramolecular complexes |
| US20070010465A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| US20070010486A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
| US20070009532A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar |
| US20070010487A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
| US20070010485A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
| US20090130156A1 (en) * | 2005-04-22 | 2009-05-21 | Endura S.P.A. | Innovative formulation |
| RU2448120C1 (en) * | 2010-11-01 | 2012-04-20 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Clathrate complexes of beta-cyclodextrin with 1-{[6-bromo-1-methyl-5-methoxy-2-phenylthiomethyl-1-h-indol-3-yl]carbonyl}-4-benzylpiperazine, having antiviral activity, synthesis and use thereof |
| WO2012115538A1 (en) | 2011-02-21 | 2012-08-30 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Clathrate complex of cyclodextrin or arabinogalactan with 9-phenyl-sym-octahydroselenoxanthene |
| RU2570382C1 (en) * | 2014-12-10 | 2015-12-10 | Общество с ограниченной ответственностью "ЛАЙФ САЙНСЕС ОХФК" | Pharmaceutical composition and medicinal agent based on clathrate complex of 7-brom-5-(ortho-chlorophenyl)-2,3-dihydro-1h-1,4-benzodiazepin-2-one and cyclodextrin, methods for producing it (versions) |
| US10149478B2 (en) | 2005-04-22 | 2018-12-11 | Endura S.P.A. | Biologically active formulation |
| WO2019215645A1 (en) * | 2018-05-09 | 2019-11-14 | Adama Makhteshim Ltd. | Use of cyclodextrins as agrochemical delivery system |
| WO2020223393A1 (en) * | 2019-04-30 | 2020-11-05 | Taka Usa, Inc. | METHODS FOR FORMING INCLUSION COMPLEXES WITH HYDROPHILIC β-CYCLODEXTRIN DERIVATIVES AND COMPOSITIONS THEREOF |
| CN112384066A (en) * | 2018-06-01 | 2021-02-19 | 拜耳作物科学有限合伙公司 | Stable fungicidal compositions comprising cyclodextrins |
| CN115581644A (en) * | 2022-09-20 | 2023-01-10 | 陕西畅想制药有限公司 | Microencapsulated kava pepper extract and preparation method and application thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU206605B (en) * | 1989-07-31 | 1992-12-28 | Chinoin Gyogyszer Es Vegyeszet | Synergetic artropodicide compositions containing pyrethroides as active components |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4228160A (en) * | 1978-01-27 | 1980-10-14 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Inclusion complex of cyclodextrin and indomethacin and a process for the preparation thereof, method of use and pharmaceutical composition |
| US4407795A (en) * | 1981-07-16 | 1983-10-04 | American Cyanamid Company | Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use |
| US4424209A (en) * | 1982-06-21 | 1984-01-03 | Key Pharmaceuticals, Inc. | 3,4-Di-isobutyryloxy-N- 3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl!-beta-phenethylamine cyclodextrin complexes |
-
1982
- 1982-11-09 HU HU823597A patent/HU190818B/en not_active IP Right Cessation
-
1983
- 1983-11-03 GB GB08329345A patent/GB2131426B/en not_active Expired
- 1983-11-04 DE DE19833339840 patent/DE3339840A1/en not_active Withdrawn
- 1983-11-07 FR FR8317644A patent/FR2535720B1/en not_active Expired
- 1983-11-09 US US06/550,478 patent/US4524068A/en not_active Expired - Fee Related
- 1983-11-09 JP JP58210680A patent/JPS59152381A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4228160A (en) * | 1978-01-27 | 1980-10-14 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Inclusion complex of cyclodextrin and indomethacin and a process for the preparation thereof, method of use and pharmaceutical composition |
| US4407795A (en) * | 1981-07-16 | 1983-10-04 | American Cyanamid Company | Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use |
| US4424209A (en) * | 1982-06-21 | 1984-01-03 | Key Pharmaceuticals, Inc. | 3,4-Di-isobutyryloxy-N- 3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl!-beta-phenethylamine cyclodextrin complexes |
Non-Patent Citations (1)
| Title |
|---|
| The Merck Index 9th Ed. (1976), p. 7273, No. 7270. * |
Cited By (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775749A (en) * | 1983-08-08 | 1988-10-04 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Inclusion compound of eicosapentaenoic of acid and food product containing the same |
| US4777162A (en) * | 1983-08-08 | 1988-10-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Inclusion compound of eicosapentaenoic acid and food product containing the same |
| US4831022A (en) * | 1983-08-08 | 1989-05-16 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Inclusion compound of eicosapentaenoic acid and food product containing the same |
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4672112A (en) * | 1984-06-08 | 1987-06-09 | Magyar Tudomenyos Akademia Novenyvedelmi Kutato Intezete | β-Cyclodextrine complex of benzene sulphonyl urea derivatives |
| US4923853A (en) * | 1985-01-07 | 1990-05-08 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. | Process for enhancing the activity of plant protecting agents by using cyclodextrin |
| US4935407A (en) * | 1986-09-23 | 1990-06-19 | Akzo N.V. | Thermochemiluminescent cyclodextrin complexes |
| US4983586A (en) * | 1987-12-30 | 1991-01-08 | University Of Florida | Pharmaceutical formulations for parenteral use |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US5017566A (en) * | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| US5024998A (en) * | 1987-12-30 | 1991-06-18 | University Of Florida | Pharmaceutical formulations for parenteral use |
| US4950682A (en) * | 1988-02-05 | 1990-08-21 | Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. | Arthropodicidal compositions |
| US5730969A (en) * | 1988-10-05 | 1998-03-24 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5079000A (en) * | 1988-11-24 | 1992-01-07 | Kurita Water Industries Ltd. | Clathrate composition including essential oils and method of using same |
| US5314877A (en) * | 1990-11-21 | 1994-05-24 | Hokkaido Sugar Co., Ltd. | Water-soluble pentacyclic triterpene composition and method for producing the same |
| US5221735A (en) * | 1991-02-25 | 1993-06-22 | Hoffmann-La Roche Inc. | Cyclodextrin-polyene inclusion complexes |
| US6583125B2 (en) | 1992-06-19 | 2003-06-24 | Supergen, Inc. | Formulation of nitrogen mustard |
| US5804568A (en) * | 1992-06-19 | 1998-09-08 | Supergen, Inc. | Pharmaceutical formulation |
| US20050043225A1 (en) * | 1992-06-19 | 2005-02-24 | Supergen, Inc. | Pharmaceutical formulation |
| US20040014695A1 (en) * | 1992-06-19 | 2004-01-22 | Supergen, Inc. | Pharmaceutical formulation |
| US6218374B1 (en) | 1992-06-19 | 2001-04-17 | Supergen, Inc. | Pharmaceutical formulation |
| US5506216A (en) * | 1993-04-23 | 1996-04-09 | Boehringer Mannheim Gmbh | Cyclodextrin-biocide complex |
| US6048845A (en) * | 1993-09-03 | 2000-04-11 | Supergen, Inc. | Pharmaceutical formulation |
| US5824668A (en) * | 1996-11-07 | 1998-10-20 | Supergen, Inc. | Formulation for administration of steroid compounds |
| WO2000002557A1 (en) * | 1998-07-10 | 2000-01-20 | Investigations Therapeutiques Essais Cliniques Services | Use of an inhibitor of cytochrome p450 optionally combined with an antifungal agent for treating mycoses |
| FR2780889A1 (en) * | 1998-07-10 | 2000-01-14 | Concept | USE OF A P450 CYTOCHROME INHIBITOR IN ASSOCIATION WITH AN ANTIFUNGAL FOR THE TREATMENT OF MYCOSES |
| US20020068720A1 (en) * | 2000-08-22 | 2002-06-06 | Sims Sandra M. | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading |
| US6989381B2 (en) | 2000-08-22 | 2006-01-24 | Pharmacia Corporation | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading |
| US20040071775A1 (en) * | 2001-07-31 | 2004-04-15 | Zhiwei Jiang | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| US7074824B2 (en) | 2001-07-31 | 2006-07-11 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| US6962944B2 (en) | 2001-07-31 | 2005-11-08 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| US20050245599A1 (en) * | 2001-07-31 | 2005-11-03 | Zhiwei Jiang | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| US6958146B2 (en) | 2003-05-28 | 2005-10-25 | Bug Buster Ltd. | Compounds to affect insect behavior and to enhance insecticides |
| US20040242699A1 (en) * | 2003-05-28 | 2004-12-02 | Bug Buster Ltd. | Compounds to affect insect behavior and to enhance insecticides |
| WO2005039287A3 (en) * | 2003-10-27 | 2005-06-23 | Endura Spa | Formulation of a synergistic insecticidal composition as a cyclodextrin-complex |
| WO2005039287A2 (en) | 2003-10-27 | 2005-05-06 | Endura S.P.A. | Formulation of a synergistic insecticidal composition as a cyclodextrin-complex |
| CN1870889B (en) * | 2003-10-27 | 2011-06-29 | 恩德拉（共同）股份公司 | Formulation of a synergistic insecticidal composition as a cyclodextrin-complex |
| US20070072827A1 (en) * | 2003-10-27 | 2007-03-29 | Oreste Piccolo | Insecticide formulation |
| US8337871B2 (en) * | 2003-10-27 | 2012-12-25 | Endura S.P.A. | Insecticide formulation |
| US20060189690A1 (en) * | 2003-11-14 | 2006-08-24 | Dunham Charles F | Compounds to affect insect behavior and/or bird behavior |
| US7867479B2 (en) | 2003-11-14 | 2011-01-11 | Bug Buster, Ltd. | Compounds to affect insect behavior and/or bird behavior |
| WO2006111570A2 (en) | 2005-04-22 | 2006-10-26 | Endura S.P.A. | Biologically active formulation based on cyclodextrin supramolecular complexes |
| CN101163399B (en) * | 2005-04-22 | 2012-09-26 | 恩德拉（共同）股份公司 | New biologically active formulation |
| WO2006111570A3 (en) * | 2005-04-22 | 2007-02-01 | Endura Spa | Biologically active formulation based on cyclodextrin supramolecular complexes |
| US9775340B2 (en) | 2005-04-22 | 2017-10-03 | Endura S.P.A. | Biologically active formulation |
| US20090130155A1 (en) * | 2005-04-22 | 2009-05-21 | Endura S.P.A. | Biologically Active Formulation |
| US20090130156A1 (en) * | 2005-04-22 | 2009-05-21 | Endura S.P.A. | Innovative formulation |
| US10149478B2 (en) | 2005-04-22 | 2018-12-11 | Endura S.P.A. | Biologically active formulation |
| AU2006237375B2 (en) * | 2005-04-22 | 2011-11-24 | Endura S.P.A. | Biologically active formulation based on cyclodextrin supramolecular complexes |
| US8025894B2 (en) | 2005-04-22 | 2011-09-27 | Endura S.P.A. | Innovative formulation |
| US20070010487A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
| US20070009532A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar |
| US20070010465A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
| US20070010486A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
| US20070010485A1 (en) * | 2005-07-06 | 2007-01-11 | Jeff Schwegman | Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins |
| EA022693B1 (en) * | 2010-11-01 | 2016-02-29 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания" Медбиофарм" | CLATHRATE COMPLEXES OF β-CYCLODEXTRIN WITH 1-{[6-BROMO-1-METHYL-5-METHOXY-2-PHENYLTHIOMETHYL-1H-INDOLE-3-YL]CARBONYL}-4-BENZYLPIPERAZINE HAVING ANTIVIRAL ACTIVITY, THE PRODUCTION AND USE THEREOF |
| RU2448120C1 (en) * | 2010-11-01 | 2012-04-20 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Clathrate complexes of beta-cyclodextrin with 1-{[6-bromo-1-methyl-5-methoxy-2-phenylthiomethyl-1-h-indol-3-yl]carbonyl}-4-benzylpiperazine, having antiviral activity, synthesis and use thereof |
| WO2012060738A1 (en) * | 2010-11-01 | 2012-05-10 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | CLATHRATE COMPLEXES OF β-CYCLODEXTRIN WITH 1-{[6-BROMO-1-METHYL-5-METHOXY-2-PHENYLTHIOMETHYL-1-H-INDOLE-3-YL]CARBONYL}-4-BENZYLPIPERAZINE HAVING ANTIVIRAL ACTIVITY, THE PRODUCTION AND USE THEREOF |
| WO2012115538A1 (en) | 2011-02-21 | 2012-08-30 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Clathrate complex of cyclodextrin or arabinogalactan with 9-phenyl-sym-octahydroselenoxanthene |
| RU2570382C1 (en) * | 2014-12-10 | 2015-12-10 | Общество с ограниченной ответственностью "ЛАЙФ САЙНСЕС ОХФК" | Pharmaceutical composition and medicinal agent based on clathrate complex of 7-brom-5-(ortho-chlorophenyl)-2,3-dihydro-1h-1,4-benzodiazepin-2-one and cyclodextrin, methods for producing it (versions) |
| WO2019215645A1 (en) * | 2018-05-09 | 2019-11-14 | Adama Makhteshim Ltd. | Use of cyclodextrins as agrochemical delivery system |
| CN112135519A (en) * | 2018-05-09 | 2020-12-25 | 阿达玛克西姆股份有限公司 | Use of cyclodextrins as agrochemical delivery systems |
| CN112384066A (en) * | 2018-06-01 | 2021-02-19 | 拜耳作物科学有限合伙公司 | Stable fungicidal compositions comprising cyclodextrins |
| WO2020223393A1 (en) * | 2019-04-30 | 2020-11-05 | Taka Usa, Inc. | METHODS FOR FORMING INCLUSION COMPLEXES WITH HYDROPHILIC β-CYCLODEXTRIN DERIVATIVES AND COMPOSITIONS THEREOF |
| CN115581644A (en) * | 2022-09-20 | 2023-01-10 | 陕西畅想制药有限公司 | Microencapsulated kava pepper extract and preparation method and application thereof |
| CN115581644B (en) * | 2022-09-20 | 2023-11-03 | 陕西畅想制药有限公司 | Microencapsulated kava extract and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2131426A (en) | 1984-06-20 |
| DE3339840A1 (en) | 1984-05-10 |
| JPS59152381A (en) | 1984-08-31 |
| FR2535720B1 (en) | 1986-02-28 |
| FR2535720A1 (en) | 1984-05-11 |
| GB2131426B (en) | 1986-08-13 |
| HU190818B (en) | 1986-11-28 |
| GB8329345D0 (en) | 1983-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4524068A (en) | Cyclodextrin inclusion complex of piperonyl butoxide | |
| US3546813A (en) | Fungicidal compositions | |
| US3513241A (en) | Fungicidal and fungistatic n-(dialkylaminoalkyl) - carbamic acid and thiocarbamic acid esters | |
| EP0806895B2 (en) | Insecticidal combinations including an insecticide from the chloronicotinyl family and an insecticide having a pyrazole, pyrrole or phenylimidazole group | |
| CZ124894A3 (en) | Phenylhydrazine derivatives, a pesticidal agent containing such compounds and method of controlling undesired insects | |
| FR2641277A1 (en) | Azolylmethylcyclopentanebenzylidene or -cyclopentenebenzylidene and use as fungicide | |
| US4804653A (en) | Thiomethyl-substituted organosilane compounds and their use as pesticides | |
| EP0068297B1 (en) | A new insecticidal composition, processes for its production and its use | |
| US2420928A (en) | Dialkoxyaryl trichloromethyl methane compounds as insecticides | |
| US4964897A (en) | Alditol ester derivatives of triclopyr, their preparation and herbicidal use thereof | |
| JPS5821602B2 (en) | insecticide composition | |
| US5091400A (en) | Clathrate compound | |
| FR2622582A1 (en) | IMIDAZOLE OR TRIAZOLE COMPOUNDS, USE THEREOF AS FUNGICIDE, PREPARATION METHOD | |
| US4627981A (en) | Attractant-ingestion stimulant preparations for Periplaneta americana L | |
| US3272695A (en) | Vinyl-sulphonic acid ester fungicides | |
| US4871748A (en) | Phenylpropargylamine derivatives | |
| US4857541A (en) | Substituted benzimidazole fungicide | |
| US5780515A (en) | Benzoquinone and hydroquinone derivatives for use as insect feeding deterrents | |
| DE19530123C2 (en) | Oxazolinone derivatives, process for their preparation and their use | |
| JPS5953401A (en) | Improved agricultural and horticultural fungicidal preparation | |
| Szejtli | Fungicidal Activity of Benomyl in Presence of β-Cyclqdextrin | |
| IL46984A (en) | N-(phenyl(or 4'-fluorophenyl)-carbamoyl)-4-methylpiperidine derivatives and herbicidal compositions containing them | |
| JPH026721B2 (en) | ||
| FR2598408A1 (en) | PROPARGYLOXYBENZENE DERIVATIVES: THEIR PREPARATION AND FUNGICIDAL COMPOSITIONS CONTAINING SAME | |
| US3444273A (en) | Molecular compounds of o,o-dimethyl-carbamoylmethyl dithiophosphate and an alkyl phenol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:SZEJTLI, JOZSEF;BUDAI, ZSUZSANNA;RADVANY, ERZSEBET;AND OTHERS;REEL/FRAME:004235/0475 Effective date: 19831019 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| LAPS | Lapse for failure to pay maintenance fees | ||
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 19930620 |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |